Deborah Pittillo
Payments from drug & device makers
Across 288 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- AbbVie$907
- Amgen$683
- Lilly USA, LLC$324
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$282
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $1,371 |
| Novo Nordisk | 58 | $1,166 |
| AbbVie | 45 | $907 |
| Amgen | 28 | $683 |
| Lilly USA, LLC | 19 | $324 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $282 |
| Boehringer Ingelheim | 9 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $207 |
| Johnson & Johnson | 13 | $200 |
| Abbott | 7 | $161 |
| Pfizer | 9 | $146 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Exact Sciences | 3 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| GSK | 4 | $71 |
| Novartis | 4 | $58 |
| Corium, LLC | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $53 |
| Bayer | 2 | $45 |
| Astellas Pharma US Inc | 2 | $44 |
| Nevro Corp. | 2 | $36 |
| Evofem Biosciences, Inc. | 2 | $35 |
| IBSA Pharma Inc. | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,585 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $120,125 |
| JardianceEmpagliflozin | 74 | $89,728 |
| MounjaroTirzepatide | 66 | $70,462 |
| EliquisApixaban | 62 | $45,866 |
| Tolvaptan | 13 | $38,138 |
| XareltoRivaroxaban | 29 | $27,843 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $20,373 |
| Nurtec OdtRimegepant Sulfate | 11 | $17,206 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $16,139 |
| Repatha SureclickEvolocumab | 18 | $11,116 |
| MyrbetriqMirabegron | 16 | $10,529 |
| ZoloftSertraline Hcl | 12 | $10,432 |
| LinzessLinaclotide | 19 | $10,177 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,057 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $8,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,166 | $120,12588 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $258 | $99,78596 claims |
| Lilly USA, LLCMounjaro | $324 | $70,46266 claims |
| PfizerEliquis, Nurtec Odt | $146 | $63,07273 claims |
| Johnson & JohnsonXarelto | $200 | $27,84329 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $907 | $13,97554 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $10,52916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Arden
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.